Diligence memo · auto-generated · as of July 2, 2026
Gracili Therapeutics, Inc.
Gracili Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Gracili Therapeutics, Inc. operates in Pharmaceuticals, based in RESEARCH TRIANGLE PARK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Gracili Therapeutics, Inc. has raised $100K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $100K on 2020-03-09.
Most recent recorded round closed around 2020-03-09.
Valuation (modeled)modeled
Provath models Gracili Therapeutics, Inc. at approximately $4.7M (range $56K–$54M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.35× the median modeled value of Pre-Seed Pharmaceuticals companies in 2019–2021 (46 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 6.3 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 1% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 9% of those peers.
Closest niche peers: Elion Oncology, Inc., Cyclone Therapeutics, Inc., Sonnet Biotherapeutics, Inc., Fastball Capital Group, Llc, TamRx, LLC.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.